Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-08-30
2011-08-30
Duffy, Patricia A (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S657000
Reexamination Certificate
active
08008284
ABSTRACT:
Propargylamine, propargylamine derivatives including N-propargyl-1-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or treatment of cardiovascular disorders, diseases and conditions.
REFERENCES:
patent: 3297527 (1967-01-01), Elslager
patent: 4861800 (1989-08-01), Buyske
patent: 5151419 (1992-09-01), Perenyi et al.
patent: 5151449 (1992-09-01), Milgram
patent: 5169868 (1992-12-01), Yu et al.
patent: 5192808 (1993-03-01), Ruehl et al.
patent: 5225446 (1993-07-01), Milgram
patent: 5242950 (1993-09-01), Fries Hastings
patent: 5276057 (1994-01-01), Milgram et al.
patent: 5387612 (1995-02-01), Youdim et al.
patent: 5387615 (1995-02-01), Milgram et al.
patent: 5453446 (1995-09-01), Youdim et al.
patent: 5457133 (1995-10-01), Youdim et al.
patent: 5486541 (1996-01-01), Sterling et al.
patent: 5519061 (1996-05-01), Youdim et al.
patent: 5532415 (1996-07-01), Youdim et al.
patent: 5576353 (1996-11-01), Youdim et al.
patent: 5599991 (1997-02-01), Youdim et al.
patent: 5639913 (1997-06-01), Lidor et al.
patent: 5668181 (1997-09-01), Youdim et al.
patent: 5744500 (1998-04-01), Youdim et al.
patent: 5786390 (1998-07-01), Youdim et al.
patent: 5840979 (1998-11-01), Durden et al.
patent: 5891923 (1999-04-01), Youdim et al.
patent: 6251938 (2001-06-01), Chorev et al.
patent: 6251950 (2001-06-01), Durden et al.
patent: 6277886 (2001-08-01), Levy et al.
patent: 6303650 (2001-10-01), Chorev et al.
patent: 6316504 (2001-11-01), Youdim et al.
patent: 6395780 (2002-05-01), Arlt et al.
patent: 6462222 (2002-10-01), Chorev et al.
patent: 6538025 (2003-03-01), Chorev et al.
patent: 6562365 (2003-05-01), Blume et al.
patent: 6630514 (2003-10-01), Youdim et al.
patent: 2002/0019421 (2002-02-01), Biberman
patent: 2002/0064552 (2002-05-01), Blume et al.
patent: 2002/0137786 (2002-09-01), Tatton et al.
patent: 2002/0188020 (2002-12-01), Chorev et al.
patent: 0538134 (1993-04-01), None
patent: 9826775 (1998-06-01), None
patent: 9827055 (1998-06-01), None
Nwogu et al. (Circulation. 2001;104:2216-21).
Eliash et al. (J Neural Transm. 2001;108:909-23).
Betkowski et al. (Current Opinion in Cardiology (2000);15:293-303).
Klabunde, Richard, PhD (CV Pharmacology: Myocardial Infarction—Causes, Effects: Cardiovascular Pharmacology Concepts. Mar. 2007; retrieved from URL: http://www.cypharmacology.com/clinical%20topics/myocardial%20infarction.htm).
S. Eliash et al., “Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats”, Journal of Neural Transmission (2001) 108: 909-923.
K. Kitsis et al., “Introduction—cell death in heart failure”, Heart Fail Rev 13:107-109 (2008).
P. Kossmehl et al., “Mechanisms of apoptosis after ischemia and reperfusion: Role of the renin-angiotensin system”, Apoptosis 11: 347-358 2006.
Sun., “Myocardial repair/remodelling following infarction: roles of local factors”, Cardiovascular Research 81, 482-490 (2009).
Tiyyagura et al., “Left Ventricular Remodeling after Myocardial Infarction: Past, Present, and Future”, The Mount Sinai Journal of Medicine vol. 73 No. 6, pp. 840-851 (2006).
Takemura et al., “Role of apoptosis in remodeling after myocardial infarction” (Science Direct) Pharmacology & Therapeutics 104 1-16 (2004).
Abbate et al., “Pathophysiologic Role of Myocardial Apoptosis in Post-Infarction Left Ventricular Remodeling” Journal of Cellular Physiology 193:145-153 (2002).
Abassi et al., “Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline” British Journal of Pharmacology 143:371:378 (2004).
Ryan et al., “1999 Update: ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction: Executive Summary and Recommendations: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)” Circulation 100:1016-1030 (1999).
Antman et al., “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction)” J. Am Coll Cardiol., 44: 671-719 (2004).
S.B. King III et al., “2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention A Report of the American College of Cardiology/American Heart AssociationTask Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee” Circulation 117:261-295 (2008).
Bar-Am et al., “Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline” Neuroscience Letters 355:169-172 (2004).
Shite et al., “Selegiline improves cardiac sympathetic terminal function and b-adrenergic responsiveness in heart failure”, Am J. Physiol Heart Circ Physiol, 279: H1283-H1290 (2000).
Speiser et al., “Studies with rasagiline, a MAO-B inhibitor, in experimental focal ischemia in the rat”, J Neural Transm, 106:593-606 (1999).
Weinreb et al., “Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members”, The FASEB Journal express, article 10.1096 (2004).
Van de Werf et al., “Acute Myocardial Infarction (AMI) 2003”, ESC Guidelines Desk Reference, ESC Committee for Practice Guidelines to Improve the quality of clinical practice and patient care in Europe, Cardiovascular Medicine, Compendium of Abridged ESC Guidelines, European Society of Cardiology, (2008), pp. 69-75.
Fuentes et al., “Central Mediation of the Antihypertensive Effect of Pargyline in Spontaneously Hypertensive Rats”, European Journal of Pharmacology 57:21-27 (1979).
Fukasawa et al., “The Central Mechanism of the Hypotensive Effects of CLOkGYLINE and DEPkENYL in Spontaneously Hypertensive Rats”, Biogenic Amines, vol. 6. No. 6. pp. 549-557 (1989).
Hubalek et al.,“Inactivation of Purified Human Recombinant Monoamine Oxidases A and B by Rasagiline and Its Analogues”, J. Med. Chem. 47:1760-1766 (2004).
Huebner et al., N-Methyl-N-2-propynyl-1-indanamine. A Potent Monoamine Oxidase Inhibitor' Journal of Medicinal Chemistry, 9, 830-832 (1966).
Kang et al., “Apoptosis and Heart Failure A Critical Review of the Literature”, Kang et al., Circulation Research, 86, 1107-1113 (2000).
Kovelman et al., “Molecular-Biological Problems of the Creation of Drugs and Study of the Mechanism of Their Action Structure and Activity of Irreversible Inhibitors of Monoamine Oxidase”, Pharmaceutical Chemistry Journal, 24:379-390 (1990).
Maruyama et al., “The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells”, J Neural Transm, 109: 467-481 (2002).
Matyus et al., “Semicarbazide-Sensitive Amine Oxidase: Current Status and Perspectives” Current Medicinal Chemistry, 2005, 11, 1285-1298.pdf.
Yogev-Falach et al., “The involvement of mitogen-activated protein (MAP) kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline” The FASEB Journal, 16:1674-1676 (2002).
Youdim et al., Molecular Basis of Neuroprotective Activities of Rasagiline and the Anti-Alzheimer Drug TV3326 [(N-Propargyl-(3R)Aminoindan-5-YL)-Ethyl Methyl Carbamate] Cellular and Molecular Neurobiology, 2:555-573 (2001).
Youdim et al., Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived f
Abassi Zaid A.
Barac Yaron
Binah Ofer
Youdim Moussa B. H.
Browdy and Neimark PLLC
Duffy Patricia A
Simmons Chris
Technion Research and Development Foundation Ltd.
LandOfFree
Methods for treatment of cardiovascular disorders and diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treatment of cardiovascular disorders and diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of cardiovascular disorders and diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2728272